A Clinical Investigation of Pivmecillinam, a Novel ß-Lactam Antibiotic, in the Treatment of Urinary Tract Infections
Pivmecillinam (FL1039) is the pivaloyloxymethyl ester of mecillinam (FL1060) which has considerable in vitro activity against Enterobacteriacae.
Thirty eight hospital inpatients who had proven urinary tract infections were treated with 400 mgs of pivmecillinam 4 times daily for 5–7 days. The MIC of mecillinam to the infecting organisms was determined as were the serum and urinary concentrations of the antibiotic.
The patients were followed up for 4–6 weeks after the end of treatment. Three patients were lost to follow up. Of the 35 patients who were adequately followed up, 29 (83%) were classified as cured and there were 6 failures. Reported side effects were of a minor nature.
KeywordsUrinary Tract Infection Minimum Inhibitory Concentration Hospital Inpatient Proteus Mirabilis Prostatic Hypertrophy
Unable to display preview. Download preview PDF.
- Christoffersen, J.C., Iversen, H.G., Jacobsen, J., Korner, B., Petersen, H.K., Rasmussen, F. and Tybring, L. FL1039 in bacteriuria following prostatectomy. Scandinavian Journal of Urology and Nephrology. (In Press).Google Scholar
- Lund, F., and Tybring, H., 6 ß-amidinopenicillanic acids a new group of antibiotics. Nature, New Biology 236: 135–137, (1972).Google Scholar
- Reeves, D.S., Faiers, M.C., Pursell, R.E., and Brumfitt, W. Trimethoprim-Sulphamethoxazole: Comparative study in urinary tract infections in hospital. British Medical Journal l: 541–544, (1969).Google Scholar
- Reeves, D.S., Wise, R., and Bywater, M.J. A laboratory evaluation of a novel ß-lactam antibiotic mecillinam; a treatment for bacterial infection. (To be published).Google Scholar
- Roholt, K., Nielsen, B., and Kristensen, E. Pharmacokinetic studies with mecillinam and pivmecillinam. (In Press).Google Scholar